Abstract: Disclosed is a nucleic acid-polypeptide nano-pharmaceutical composition for treating and preventing human papilloma virus infection. A small interfering nucleic acid siRNA molecule used for inhibiting and treating various diseases caused by a HPV infection can block the virus replication life cycle by means of targeted inhibition of the expression of the HP16/18 key gene, reduce a viral infection and finally remove viruses. A pharmaceutical composition based on the siRNA molecule comprises a siRNA molecule and another molecule, including a siRNA molecule for inhibiting PD-1/PD-L1, a small molecule compound against a HPV infection, a therapeutic mRNA/neoantigen vaccine, and the like. The siRNA molecule and other anti-HPV drugs are coupled by means of a specific chemical bond to form a new coupled molecule, and the composition further includes a pharmaceutically acceptable polypeptide polymer nano-introduction carrier. In some embodiments, the carrier is a histidine-lysine polypeptide polymer nanocarrier.

Abstract: Provided herein are nucleic acid interference pharmaceutical compositions, and drugs for treating colorectal cancer, gastric cancer and prostate cancer. For two targets (TGF-?1 and MyD88) related to tumor microenvironment and tumor metastasis in colorectal cancer, gastric cancer, and prostate cancer, an MyD88/TGF-?1 dual-target nucleic acid interference pharmaceutical composition (composition number STP500) is designed and selected, which includes an active ingredient and a pharmaceutically acceptable carrier. The active ingredient includes a first active ingredient capable of inhibiting and silencing the expression of the MyD88 gene and a second active ingredient capable of inhibiting and silencing the expression of TGF-?1 gene.

Abstract: Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.

Abstract: The techniques of the present disclosure provide a method of inhibiting tumor growth in a tissue of a mammal. The method includes administering to the mammal a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGF?1 protein, an siRNA molecule that binds to an mRNA that codes for VEGFR2 protein, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable polypeptide polymer. The techniques of the present disclosure also provide for additional methods for using this composition.

Abstract: Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.